<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2305">
  <stage>Registered</stage>
  <submitdate>25/03/2009</submitdate>
  <approvaldate>25/03/2009</approvaldate>
  <nctid>NCT00870194</nctid>
  <trial_identification>
    <studytitle>A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin</studytitle>
    <scientifictitle>A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>H8O-CR-GWDK</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 Diabetes Mellitus</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - exenatide and sitagliptin
Treatment: drugs - exenatide and placebo

Experimental: 1 - 

Placebo Comparator: 2 - 


Treatment: drugs: exenatide and sitagliptin
exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; sitagliptin-100mg tablet orally once a day

Treatment: drugs: exenatide and placebo
exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; placebo-tablet orally once a day

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in HbA1c (Percent) - Change in HbA1c from baseline to endpoint (Week 20); difference of base percent values [X% - Y%]</outcome>
      <timepoint>Baseline to 20 Weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Patients Achieving HbA1c &lt;=7.0% - Percentage of patients whose baseline HbA1c was &gt; 7.0% achieving HbA1c &lt;=7.0% at endpoint (Week 20)</outcome>
      <timepoint>Baseline to 20 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Patients Achieving HbA1c &lt;7.0% - Percentage of patients whose baseline HbA1c was &gt;=7.0% achieving HbA1c &lt;7.0% at endpoint (Week 20)</outcome>
      <timepoint>Baseline to 20 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Patients Achieving HbA1c &lt;=6.5% - Percentage of patients whose baseline HbA1c was &gt; 6.5% achieving HbA1c &lt;=6.5% at endpoint (Week 20)</outcome>
      <timepoint>Baseline to 20 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in FSG (mmol/L) - Change in fasting serum glucose (FSG) from baseline to endpoint (Week 20)</outcome>
      <timepoint>Baseline to 20 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Body Weight (kg) - Change in body weight from baseline to endpoint (Week 20)</outcome>
      <timepoint>Baseline to 20 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Waist Circumference (cm) - Change in waist circumference from baseline to endpoint (Week 20)</outcome>
      <timepoint>Baseline to 20 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Waist-to-Hip Ratio - Change in waist-to-hip ratio from baseline to endpoint (Week20)</outcome>
      <timepoint>Baseline to 20 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>SMBG (mmol/L) - 7 point Self Monitored Blood Glucose Profiles - daily mean value (Week 20)</outcome>
      <timepoint>Baseline to 20 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Triglycerides (mmol/L) - Change in triglycerides from baseline to endpoint (Week 20)</outcome>
      <timepoint>Baseline to 20 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in HDL (mmol/L) - Change in high-density lipoprotein (HDL) cholesterol from baseline to endpoint (Week 20)</outcome>
      <timepoint>Baseline to 20 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in LDL (mmol/L) - Change in low-density lipoprotein (LDL) cholesterol from baseline to endpoint (Week 20)</outcome>
      <timepoint>Baseline to 20 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Total Cholesterol (mmol/L) - Change in total cholesterol from baseline to endpoint (Week 20)</outcome>
      <timepoint>Baseline to 20 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Hypoglycemia (Overall) - Incidence of hypoglycemic episodes experienced overall during the study</outcome>
      <timepoint>Baseline to 20 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Severe Hypoglycemia(Overall) - Incidence of severe hypoglycemia experienced overall during the study</outcome>
      <timepoint>Baseline to 20 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Nocturnal Hypoglycemia (Overall) - Incidence of nocturnal hypoglycemia experienced overall during the study</outcome>
      <timepoint>Baseline to 20 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Confirmed Hypoglycemia(Overall) - Incidence of confirmed hypoglycemia experienced overall during the study</outcome>
      <timepoint>Baseline to 20 Weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Present with type 2 diabetes

          -  Patients have been treated with a stable dose of the following for at least 3 months
             prior to screening:

               -  100 mg/day sitagliptin and

               -  =1500 mg/day metformin, or maximum tolerated dose (extended release or
                  immediate-release).

          -  Have inadequate glycemic control as evidenced by an HbA1c between 7.1% and 9%,
             inclusive.

          -  Have a body mass index (BMI) =20 kg/m2 and &lt;45 kg/m2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Are currently enrolled in, or discontinued within the last 30 days (or longer, if
             local guidelines require) from, a clinical trial involving an off-label use of an
             investigational drug or device, or concurrently enrolled in any other type of medical
             research judged not to be scientifically or medically compatible with this study.

          -  Have previously completed or withdrawn from this study or any other study
             investigating exenatide.

          -  Have a known allergy or hypersensitivity to exenatide, sitagliptin or excipients
             contained in exenatide or sitagliptin.

          -  Used drugs for weight loss (for example, orlistat, sibutramine, phenylpropanolamine,
             or similar over-the-counter medications) within 1 month of screening.

          -  Are currently treated with any of the following excluded medications:

               -  Thiazolidinediones (TZD) within 3 months of screening.

               -  Sulfonylurea (SU) within 3 months of screening.

               -  Dipeptidyl peptidase-4 [DPP-4] inhibitors, with the exception of sitagliptin,
                  within 3 months of screening.

               -  Meglitinide derivatives (for example, repaglinide or nateglinide) within 3 months
                  of screening.

               -  Alpha-glucosidase inhibitors (for example, miglitol or acarbose) within 3 months
                  of screening.

               -  Exogenous insulin within the 3 months prior to screening.

               -  Drugs that directly affect gastrointestinal motility, including, but not limited
                  to: metoclopramide, cisapride, and chronic macrolide antibiotics.

               -  Systemic corticosteroids (excluding topical and inhaled preparations) by oral,
                  intravenous (IV), or intramuscular (IM) route used regularly (for longer than 1
                  month) or used within 1 month immediately prior to screening.

               -  Any other oral antidiabetic (OAD) agent, other than sitagliptin or metformin,
                  within 3 months prior to screening.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>255</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Research Site - Adelaide</hospital>
    <hospital>Research Site - Geelong</hospital>
    <hospital>Research Site - Melbourne</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Geelong</postcode>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Mor√≥n</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Aschaffenburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Asslar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Beckum-Neubeckum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bosenheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Falkensee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Furth im Wald</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Grevenbroich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg-Othmarschen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hohenmolsen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Neuwied</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Pohlheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Speyer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaloniki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Ahmedabad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Bangalore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Coimbatore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Indore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Jaipur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gwangju</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Ulsan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Coatzacoalcos</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Guadalajara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Merida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Monterrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Tampico</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AstraZeneca</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Eli Lilly and Company</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether ceasing sitagliptin and switching to
      exenatide and metformin is non-inferior to adding exenatide to sitagliptin and metformin, in
      those patients with type 2 diabetes who are experiencing inadequate glycemic control with a
      combination of sitagliptin and metformin.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00870194</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Chief Medical Officer, MD</name>
      <address>Eli Lilly and Company</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>